A Phase 1, Single-Center, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HT-6184 in Healthy Human Subjects
Latest Information Update: 19 Sep 2023
At a glance
- Drugs HT-6184 (Primary)
- Indications Inflammation
- Focus Adverse reactions
Most Recent Events
- 19 Sep 2023 New trial record